الفهرس Only 14 pages are availabe for public view
 |  | from | 104 |  |  |
| | | from | 104 | | |
Abstract
The aim of the study: The aim of the current study was to simultaneously investigate the therapeutic potential of 1,25(OH)2D3 on OSCC cell line, and understand their underlying mechanisms of action with a focus on the screening of the possible related miRNAs biomarkers. Materials and methods: In the current study, the therapeutic potential of 1,25(OH)2D3 on OSCC cell line was investigated using Prestoblue Cell Viability assay to test the cytotoxicity effect of 1,25(OH)2D3 on OSCC cell line and to test if this effect has a dose-dependent manner. Data from this assay was used to calculate IC-50 dose to be used in the subsequent assays. In order to dig more deeply in this cytotoxicity mechanisms, two anti-cancer pathways have been investigated through two assays: Western blotting assay for investigating the cell cycle arrest pathway, and flow cytometry assay to investigate apoptosis pathway. MiRNA profiling was done in order to screen which miRNAs would be affected by 1,25(OH)2D3 treatment. Results: The results of the present study showed that 1,25(OH)2D3 inhibited the growth of the OSCC line in a dose-dependent manner. Also, the results clearly demonstrated increased apoptosis of the cells treated with 1,25(OH)2D3 as compared to cells treated with the vehicle when analyzed with flow cytometry. The expression levels of 800 miRNAs were evaluated. Some miRNAs showed aberrant expression between cells treated with 1,25(OH)2D3 and those which treated with DMSO only